(NASDAQ: ENLV) Enlivex Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 6.22%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 54.31%.
Enlivex Therapeutics's earnings in 2025 is -$13,098,000.On average, 1 Wall Street analyst forecast ENLV's earnings for 2025 to be -$10,736,235, with the lowest ENLV earnings forecast at -$10,736,235, and the highest ENLV earnings forecast at -$10,736,235.
In 2026, ENLV is forecast to generate -$13,599,232 in earnings, with the lowest earnings forecast at -$13,599,232 and the highest earnings forecast at -$13,599,232.